Evidence map›Paper›PMID 33281191›Full record

ArticleCancer gene therapy2021

Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse.

Sara Ciceri, Rafaela Montalvão-de-Azevedo, Amir Tajbakhsh, Alessia Bertolotti, Rosalin Dolores Spagnuolo, Luna Boschetti, Maria Capasso, Paolo D'Angelo, Annalisa Serra, Francesca Diomedi-Camassei and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Cancers · 2022
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 3 countries.

Sara Ciceri *Molecular Bases of Genetic Risk and Genetic Testing Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Rafaela Montalvão-de-Azevedo *Molecular Bases of Genetic Risk and Genetic Testing Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID http://orcid.org/0000-0002-3868-7894
Amir TajbakhshMolecular Bases of Genetic Risk and Genetic Testing Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Alessia BertolottiDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Rosalin Dolores SpagnuoloDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Luna BoschettiPediatric Oncology Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Maria CapassoDepartment of Pediatric Oncology, Ospedale Santobono-Pausilipon, Naples, Italy.
Paolo D'AngeloPediatric Hematology and Oncology Unit, ARNAS Civico, Di Cristina e Benfratelli Hospitals, Palermo, Italy.
Annalisa SerraDepartment of Hematology/Oncology and Stem Cell Transplantation, Bambino Gesù Pediatric Hospital and IRCCS, Rome, Italy.
Francesca Diomedi-CamasseiPathology Unit, Department of Laboratories, Bambino Gesù Pediatric Hospital and IRCCS, Rome, Italy.
Mariaclaudia MeliUnit of Pediatric Hematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy.
Marilina NantronDepartment of Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Paola QuarelloPediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
Anna Maria BuccolieroDivision of Pathology, Children's Hospital A. Meyer-University of Florence, Florence, Italy.
Angela TamburiniHematology Oncology and HSCT Unit, Children's Hospital A.Meyer-University of Florence, Florence, Italy.
Chiara Maura CiniselliBioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paolo VerderioBioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paola ColliniDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paolo RadiceMolecular Bases of Genetic Risk and Genetic Testing Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID http://orcid.org/0000-0001-6298-4111
Filippo Spreafico *Pediatric Oncology Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Daniela Perotti *Molecular Bases of Genetic Risk and Genetic Testing Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. daniela.perotti@istitutotumori.mi.it.ORCID http://orcid.org/0000-0002-6703-2889
Fondazione IRCCS Istituto Nazionale dei Tumori · ITBambino Gesù Children's Hospital · ITMeyer Children's Hospital · ITInstituto Nacional de Câncer - INCA · BRIstituto Giannina Gaslini · ITMashhad University of Medical Sciences · IRSantobono Children's Hospital · ITUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whereas 90% of patients with Wilms tumor (WT) reach cure, approximately half of patients developing a recurrent tumor die of the disease. Therefore, to disclose events leading to recurrence represents a clinical need. To study paired primary/recurrent tumor samples, being aware of the intra-tumoral heterogeneity, might help finding these answers. We previously suggested that mutations in SIX1 and DROSHA underlie WT recurrence. With the aim to better investigate this scenario, we collected 19 paired primary/recurrent tumors and 10 primary tumors from relapsing patients and searched for mutations in the SIX1/2 genes and microRNA processing genes (miRNAPGs). We found SIX1 mutation in one case, miRNAPGs mutations in seven cases, and the co-occurrence of SIX1 and miRNAPG mutations in one case. We could observe that, whereas in primary tumors the mutations could be heterogeneously present, in all cases they were positively selected and homogeneously present in the recurrent disease, as also indicated by a "moderate" and "almost perfect" agreement (according to the Landis and Koch classification criteria) between paired samples. Analysis of SIX1/2 genes and miRNAPGs in 50 non-relapsing WTs disclosed SIX2 mutation in one case and miRNAPGs mutations in seven. A borderline statistically significant association was observed between miRNAPGs mutations and the occurrence of relapse (p value: 0.05). These data suggest that SIX1 and miRNAPGs mutations may provide an advantage during tumor progression to recurrence and can represent oncogenic drivers in WT development.

Indexed as

Homeodomain ProteinsHumansMicroRNAsMutationNerve Tissue ProteinsSurvival AnalysisWilms TumorHomeodomain ProteinsMicroRNAsNerve Tissue ProteinsSIX1 protein, humanSIX2 protein, human

Identifiers

PMID33281191
OpenAlexW3111887140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.